Skip to content

English
Français

Careers
Contact Us

About DBV
- Overview
- Leadership
Our Pipeline
- Overview
- Clinical Trials
- VIASKIN^® peanut patch
- VIASKIN^® milk patch
- VIASKIN^® milk patch for EoE
- Expanded Access Program
Our Science
Investors
Newsroom
- Press Releases
- Media Kit

News

News

Select Year
Search News

Found 490 Results

Page 6 of 49« First «...4 567 8...20 30 40...»Last »

January 13, 2025

Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

January 8, 2025

DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study

December 11, 2024

DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin^® Peanut Patch in Toddlers 1 – 3 Years-Old

December 2, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024

November 11, 2024

DBV Technologies Announces Plan to Implement ADS Ratio Change

November 6, 2024

DBV Technologies Reports Third Quarter 2024 Financial Results

October 22, 2024

DBV Announces Positive Regulatory Updates for the Viaskin^® Peanut Patch in the United States and Europe

October 18, 2024

DBV Technologies to Participate in Upcoming ACAAI 2024 Congress

October 14, 2024

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

September 23, 2024

DBV Technologies Completes Screening for the VITESSE Phase 3 Clinical Trial

Page 6 of 49« First «...4 567 8...20 30 40...»Last »

Investor Relations Contact

Jonathan Neely

+1 848-388-4584

jonathan.neely@dbv-technologies.com

Media Contact

Brett Whelan

+1 848-350-7622

brett.whelan@dbv-technologies.com

Subscribe to get the latest DBV press releases

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

About DBV
- Overview
- Leadership
Our Pipeline
Our Science
Investors
News
Careers
Contact Us
English
Français

Homepage
About DBV
Our Pipeline
Our Science
News
Investors
Careers
Contact Us

© 2026 DBV Technologies. All rights reserved.
Les traitements de DBV Technologies sont expérimentaux et ne sont pas approuvés par la FDA.

Terms of Use
Privacy Policy
Legal Notice
Your California Privacy Rights

Scroll to Top